Atezolizumab Market Growth Accelerated by Rising Adoption of Targeted Therapies

Atezolizumab is a monoclonal antibody used for treating various types of cancers including urothelial carcinoma, non-small cell lung cancer, and triple-negative breast cancer. It works by blocking the interaction between PD-L1 protein found on tumor cells and PD-1 protein found on T-cells, thereby helping the immune system attack the cancer cells.

The global Atezolizumab Market is estimated to be valued at US$ 308 million in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The rising adoption of targeted therapies for cancer treatment is one of the major factors accelerating the growth of the Atezolizumab Market. Atezolizumab specifically targets the PD-L1/PD-1 pathway and provides an effective treatment option with fewer side effects compared to chemotherapy. It has shown promising results in clinical trials for various cancer types. Its targeted mechanism of action helps strengthen the immune response against cancer cells. With increasing awareness about immunotherapy and its advantages, the demand for more targeted drugs like Atezolizumab is expected to surge significantly over the forecast period.

Segment Analysis

The global atezolizumab market is dominated by late-stage NSCLC segment which accounted for over 60% market share in 2023. This is owing to high prevalence of non-small cell lung cancer across the globe. Atezolizumab is one of the preferred treatment options for late-stage NSCLC patients. The drug shows survival benefits in second line treatment of late-stage NSCLC patients. In addition, increasing success rates of combination therapies with atezolizumab for late-stage NSCLC is expected to drive further growth of this segment during forecast period.

Key Takeaways

The global Atezolizumab market is expected to witness high growth.
Regional analysis: North America region currently dominates the atezolizumab market owing to high adoption of premium-priced targeted therapies and availability of favorable reimbursement policies in countries like United States. North America accounted for over 40% of global atezolizumab market share in 2023. Asia Pacific region is expected to witness highest growth during forecast period with CAGR of around 4%, due to increasing cancer incidence, improving access to cancer therapies and rising healthcare spending in countries like China and India.

Key players: Key players operating in the atezolizumab market are Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc. Among them, Roche and its subsidiary Genentech dominate the market with over 50% share as atezolizumab was developed by them and marketed under trade name Tecentriq.